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Studies have shown that nifedipine, an anti-hypertensive drug, protects against atherosclerotic pro-
gression, but the underlying mechanisms remain elusive. Oxidized low-density lipoprotein (ox-LDL) is
critically implicated in macrophage lipid deposition seen in atherosclerosis. In this study, we examined
the effects of nifedipine on some ox-LDL-associated changes in human blood-derived macrophages. We
isolated monocytes from normal human blood and differentiated them into macrophages. We then
treated these human macrophages with ox-LDL and/or nifedipine, and examined lipid accumulation and
expression levels of two scavenge receptors CD36 and SR-A as well as a protein kinase PKC-q. Nifedipine
treatment substantially reduced lipid accumulation and the expression of CD36, SR-A, and protein kinase
C (PKC)-q in human macrophages treated with ox-LDL. Silencing of PKC-q using siRNA also reduced the
expression of CD36 and SR-A in these cells. Our results thus suggest that nifedipine may inhibit
atherosclerosis by reducing ox-LDL-induced lipid deposition through suppression of the CD36/SR-A-
mediated uptake of ox-LDL by macrophages via a PKC-q-dependent mechanism.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atherosclerosis is a chronic inﬂammatory disease characterized
by early and prolonged presence of macrophages within the arterial
intima [1]. During atherogenesis, circulating monocytes migrate
into the arterial intima where the majority of them differentiate
into macrophages [2]. After uncontrolled uptake of ox-LDL via
different scavenger receptors, macrophages are transformed into
lipid-laden foam cells and release growth factors and cytokines that
drive the growth and inﬂammatory responses of atherosclerotic
plaque [3]. The scavenger receptors CD36 and SR-A are the main
receptors for ox-LDL on the macrophage membrane [4]. SR-A, a
member of the class A scavenger receptor family, has been impli-
cated in atherosclerosis [5]. CD36 belongs to the scavenger receptor
B family, and its activation has also been involved in foam cell
formation. SR-A and CD36 may account for greater than 90% of the
lipid uptake by macrophages treated with oxidized LDL [6].
Nifedipine is a calcium channel blocker and it has been widely
used to treat hypertension. Nifedipine can inhibit vascular smooth.
tion.
Inc. This is an open access article umuscle cell proliferation and reactive oxygen species (ROS) pro-
duction via an AMP-activated protein kinase signaling pathway [7].
In a clinical study, Effect of Long-acting Nifedipine onMortality and
Cardiovascular Morbidity in Patients with Hypertension (ACTION)
and Symptomatic Stable Angina Trial, the cardiovascular morbidity
of patients with symptomatic coronary artery disease and hyper-
tension are signiﬁcantly reduced by the addition of nifedipine-GITS
to the basic treatment [8]. Nifedipine also improves endothelial
function as well as coronary and brachial artery vasodilation to Ach
in patients with coronary artery disease [9]. Although nifedipine
has been shown to have anti-hypertensive and anti-atherogenic
effects [10], the underlying mechanisms remain largely unknown.
In this study, we explored the effects of nifedipine on the lipid
accumulation and scavenge receptor expression associated with
ox-LDL in human blood-derived macrophages.
2. Materials and methods
2.1. Materials
Nifedipine was purchased from Sigma (USA). Total RNA extrac-
tion reagent RNAiso Plus, PrimeScript RT reagent kit, and SYBR-
Green PCR kit were purchased from Takara (Japan). Immunoblot
reagents were purchased from the Beyotime Institute ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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available from commercial sources.
2.2. Cell culture
Human peripheral blood monocytes (PBM) were isolated from
healthy volunteers using Ficoll/Hypaque gradient centrifugation.
The pooled monocytes from the volunteers were incubated in
DMEM supplemented with 10% autologous serum for 10 days for
differentiation into macrophages.
2.3. Effects of nifedipine on lipid accumulation induced by ox-LDL
in human macrophages
Human macrophages were treated with control, ox-LDL (1 mg/
ml) þ nifedipine (10 nmol/l), or ox-LDL (1 mg/ml) for 24 and 48 h.
Lipid depostion was visualized after oil red O staining.
2.4. RNA isolation and quantitative real-time PCR analyses
Total RNAwas extracted using RNAiso Plus reagent in accordance
with manufacturer's instructions. PCR primers were synthesized by
Shanghai Sangon (Shanghai, China). The forward and reverse primer
sequences for each gene are listed below: CD36: 50-GTC TTC CCA ATA
AGC ATG TCT CC-30 and 50-GTC TTC CCA ATA AGC ATG TCT CC-30; SR-
A: 50-TGA ACG AGA GGA TGC TGA CTG-30 and 50-TGT CAT TGA ACG
TGC GTC AAA-30; PKC-q: 50-ATC CTG GAG AGA GCT CTC CAA T-30 and
50-CGC CTG AGC TCT CTA TCA TCG T-30; and GAPDH: 50-AGG CCG
GTG CTG AGT ATG TC-30 and 50-TGC CTG CTT CAC CAC CTT CT-30.
Real-time PCR was performed with SYBR® Premix Ex Taq™ II, on a
Bio-Rad iCycler with an iQ3.1 real-time PCR system. The DD Ct
method was used to determine relative abundance of mRNA, and
GAPDH was used as an internal invariant control.
2.5. Western blot analysis
Cells were harvested and protein extracts prepared in accor-
dance with the manufacturer's instructions. Immunoblot analysis
[12% SDS-PAGE; 30 mg protein per lane] was then performed using
rabbit anti-CD-36, anti-SR-A, anti- PKC-q or anti-GAPDH (Abcam,
USA)-speciﬁc antibodies. Proteins were visualized using enhanced
chemiluminescence.
2.6. Selection of PKC-q siRNAs in human macrophages
The PKC-q-siRNA speciﬁc for human PKC-q and nonsilencing
(control) siRNAs were synthesized by Shanghai Genechem
(Shanghai, China). Human macrophages (1  106 cells/well) were
transfected using Lipofectamine 2000 (Invitrogen). Following 48 h
transfection, a siRNA fragment of PKC-q suppressed expression of
PKC-q gene by 70% according to RT-PCR analyses. This siRNA (PKC-
q-siRNA) was used for the experiments and its sequence is 5-ATC
TGC ATG CTG ATG ACT T-3.
2.7. PKC-q siRNA transfection and Western blot analyses
Human macrophages were grown in culture ﬂasks at a density
of 1107/ml for 12 h, washed with PBS, and then treated with PKC-
q-siRNA or control siRNA in the serum-free DMEM containing ox-
LDL at 10 mg/ml and in absence or presence of nifedipine
(10 nmol/L). The cells were harvested 96 h later for protein
extraction and immunoblotting [12% SDS-PAGE; 60 mg protein per
lane] using rabbit anti-CD36, anti-SR-A, anti-PKC-q and anti-
GAPDH (Abcam, USA)-speciﬁc antibodies.2.8. Statistical analyses
Data are expressed as mean ± standard error of the mean (SEM).
Results were analyzed using One-way ANOVA with SPSS 13.0
software. P < 0.05 was considered statistically signiﬁcant. All ex-
periments were performed at least in triplicate.
3. Results
3.1. Nifedipine inhibits ox-LDL-induced lipid accumulation in
human macrophages
Macrophages accumulate lipids in the cytoplasm after treatment
with ox-LDL. To determine if nifedipine modulates this phenome-
non, we treated human peripheral blood monocyte (PBM)-derived
macrophageswith ox-LDL in the absence or presence of nifedipine. A
substantial reduction in Oil red O-stained lipids was observed in
macrophages treated with ox-LDL (1 mg/ml) and nifedipine
(10 nmol/l) relative to ox-LDL (1 mg/ml) alone after 24 h or 48 h of
treatment (Fig.1). This observation indicates that nifedipine prevents
ox-LDL-induced lipid accumulation in human macrophages.
3.2. Nifedipine suppresses ox-LDL-induced increases in expression
levels of CD36, SR-A, and PKC-q in human macrophages
To determine the potential mechanisms involved in the above
observation, we ﬁrst examined CD36 and SR-A, two cell surface
receptors critically implicated in the uptake of ox-LDL, and PKC-q, a
protein kinase involved in lipid-associated signal transduction. We
found that the mRNA expression levels of CD36, SR-A, and PKC-q
increased 260%, 452%, and 410%, respectively, in human macro-
phages treated with ox-LDL at 5 mg/ml (Fig. 2AeC). At 10 mg/ml, the
increases were 320%, 630%, and 550%, respectively (Fig. 2AeC).
Similar alterations were seen for the protein levels of CD36, SR-A
and PKC-q (230%, 320%, and 280% increases at 5 mg/ml of ox-LDL;
290%, 415% and 390% increases at 10 mg/ml, respectively).
(Fig. 2D–G)
We then examined whether nifedipine has any effects on the
expression of CD36, SR-A, and/or PKC-q in human macrophages
treated with ox-LDL at 10 mg/ml. Indeed, nifedipine treatment at
10 nmol/L signiﬁcantly reduced themRNA levels of CD36, SR-A, and
PKC-q by 57.0%, 65.3%, and 62.8%, respectively, in these cells
(Fig. 3AeC). Similar changes were observed when nifedipine was
used at 100 nmol/L, suggesting that there was no dose-dependent
effect in the range of the doses. Nifedipine treatment also signiﬁ-
cantly reduced the protein expression levels of CD36, SR-A, and
PKC-q by 53%, 58%, and 57.3%, respectively, in human macrophages
treated with ox-LDL at 10 mg/ml (Fig. 3DeG). These ﬁndings,
together with key roles of CD-36 and SR-A in ox-LDL uptake, sug-
gest that nifedipine may prevent ox-LDL-induced lipid accumula-
tion by suppressing cellular uptake of ox-LDL particles.
3.3. PKC-q modulates ox-LDL-induced expression of CD-36 and SR-
A in human macrophages
PKC-q senses cellular lipids to alter signal transduction, which
has the potential to alter gene expression. Therefore, we examined
whether there is any crosstalk among PKC-q, CD36 and SR-A in
human macrophages. The siRNA-mediated silencing of PKC-q, like
nifedipine at 10 nmol/l, reduced the protein levels of CD36 and SR-A
(by 73%, 79.5% for PKC-q siRNA and 52%, 59% for nifedipine,
respectively) (Fig. 4AeD). This result implies that PKC-q may be
involved in the regulation of SR-A and CD-36 expression induced by
ox-LDL in human macrophages.
Fig. 1. Nifedipine inhibits ox-LDL-induced lipid accumulation in human macrophages. Human macrophages were treated with ox-LDL (1 mg/ml) and nifedipine (10 nmol/l) or
ox-LDL alone for 24 h or 48 h and then subjected to Oil red O staining.
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Previous studies have shown that nifedipine inhibits the
expression of macrophage inﬂammatory cytokine MCP-1 via
suppressing phosphorylation and activation of PPAR, and protects
against atherosclerotic progression in apoE/mice [10]. Ox-LDL
plays a critical role in the pathogenesis of atherosclerosis [11,12].
Here we demonstrated that nifedipine prevents ox-LDL-induced
lipid accumulation in human blood-derived macrophages. WeFig. 2. Ox-LDL induces expression of CD36, SR-A and PKC-q in human macrophages. (Ae
for 24 h (DeG) The protein levels of CD36, SR-A, and PKC-q in human macrophages treate
different.further showed that nifedipine inhibits ox-LDL-associated
expression of CD36, SR-A, and PKC-q in these cells. Considering
the critical roles of CD36 and SR-A in macrophage uptake of ox-
LDL particles, our data suggest that nifedipine may protect
against atherosclerosis by inhibiting ox-LDL-induced lipid accu-
mulation in macrophages through down-regulating ox-LDL
uptake.
PKC-q is critically involved in the T cell receptor (TCR) signaling
selectively required for the activation of T cell in vivo [13]. PKC-qC) The mRNA levels CD36, SR-A and PKC-q in human macrophages treated with ox-LDL
d with ox-LDL for 48 h. Values associated with different small letters are statistically
Fig. 3. Nifedipine suppresses ox-LDL-associated expression of CD36, SR-A and PKC-q in human macrophages. (AeC) The mRNA levels CD36, SR-A and PKC-q in human
macrophages treated with ox-LDL at 10 mg/ml for 24 h in the absence or presence of nifedipine. (DeG) The protein levels CD36, SR-A and PKC-q in human macrophages treated with
ox-LDL at 10 mg/ml for 48 h in the absence or presence of nifedipine. *P < 0.05 vs control. Values associated with different small letters are statistically different.
Fig. 4. Silencing of PKC-q with siRNA suppresses ox-LDL-associated expression of CD36 and SR-A. Human macrophages were treated with ox-LDL at 10 mg/ml for 96 h in the
absence or presence of PKC-q siRNA or nifedipine at 10 nmol/L. The protein expression levels of CD36, SR-A and PKC-q were measured by Western blots and densitometry. Values
associated with different small letters are statistically different.
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nuclear factor of activated T cells (NFAT), AP-1 and NF-kB [14,15].
Mature PKC-q/ T cells cannot activate NF-kB and AP1 upon TCR
stimulation and fail to proliferate and produce interleukin 2 (IL-2)
[16]. Mice deﬁcient in other isoforms of PKC do not have the same
effects in T cell activation, thereby indicating the importance of
PKC-q in T cell activation [17]. Here we provided some evidence in
support of a role of PKC-q in regulating CD36 and SR-A expression
associated with ox-LDL in human macrophages. Detailed studies
are required to study how nifedipine alters PKC-q expression and
activation in the future.
In conclusion, our results suggest that nifedipine inhibits ox-
LDL-induced lipid deposition in human macrophages, at least in
part through inhibition of CD36 and SR-A expression via a PKC-q-
dependent pathway.Conﬂict of interest
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